Anti-DLL4 PE

*Yamanda S, Ebihara S, Asada M, Okazaki T, Niu K, Ebihara T, Koyanagi A, Yamaguchi N, Yagita H, Arai H: Role of ephrinB2 in nonproductive angiogenesis induced by Delta-like 4 blockade. Blood. 2009 Apr 9;113 (15) :3631-9, URL: http://www.ncbi.nlm.nih.gov/pubmed/19218547, *Oishi H, Sunamura M, Egawa S, Motoi F, Unno M, Furukawa T, Habib NA, Yagita H: Blockade of delta-like ligand 4 signaling inhibits both growth and angiogenesis of pancreatic cancer. Pancreas. 2010 Aug;39 (6) :897-903, URL: http://www.ncbi.nlm.nih.gov/pubmed/?term=oishi+h+sunamura+m , *Sekine C, Koyanagi A, Koyama N, Hozumi K, Chiba S, Yagita H: Differential regulation of osteoclastogenesis by Notch2/Delta-like 1 and Notch1/Jagged1 axes. Arthritis Res Ther. 2012 Mar 5;14 (2) :R45., URL: http://www.ncbi.nlm.nih.gov/pubmed/22390640

The mouse monoclonal antibody MHD4-46 recognizes the extracellular domain of DLL4 (Delta-like ligand 4), a type I transmembrane protein which plays an important role in vascular development.